Atrial fibrillation: diagnosis and management

not tolerated or not suitable in people with atrial fibrillation, offer a vitamin K antagonist. See the section on self-monitoring and self-management of vitamin K antagonists. [2021] 1.6.6 For adults with atrial fibrillation who are already taking a vitamin K antagonist and are stable, continue with their current medication and discuss the option of switching treatment at their next routine appointment, taking into account the person's time in therapeutic range. [2021] 1.6.7 Do not offer stroke prevention therapy with anticoagulation to people aged under 65 years with atrial fibrillation and no risk factors other than their sex (that is, very low risk of stroke equating to a CHA DS -VASc score of 0 for men or 1 for 2 2 women). [2021] 1.6.8 Do not withhold anticoagulation solely because of a person's age or their risk of falls. [2021] Direct-acting oral anticoagulant treatment options 1.6.9 For direct-acting oral anticoagulants recommended as options in NICE technology appraisal guidance for preventing stroke and systemic embolism in some people with atrial fibrillation, see the guidance on: • edoxaban (TA355, 2021) • apixaban (TA275, 2021) • rivaroxaban (TA256, 2021) • dabigatran etexilate (TA249, 2021). For a short explanation of why the committee made these
